Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Bristol-Myers

Intuitive Surgical

Healthcare stocks can be excellent choices for investors, offering a balance of safety and growth. Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk all have strong growth potential.

Got $500? 3 Healthcare Stocks to Buy and Hold Forever

ICON

MercadoLibre

Shin-Etsu Chemical Co Ltd

Taiwan Semiconductor Manufacturing

It is understandable for U.S. investors to be focused on the largest technology companies that have driven such strong performance for the S&P 500 over the past decade. But learning about strategies that give exposure beyond the U.S. large-cap benchmark can help you to lower portfolio-concentration risk while expanding your set of opportunities for long-term growth in the stock market.

Eight stock picks in AI, obesity drugs, e-commerce and other growth areas beyond the S&P 500

The German cartel office has approved a deal by Denmark's Novo Nordisk to purchase Cardior Pharmaceuticals, the regulator said in a statement on Thursday.

German watchdog approves Novo's acquisition of Cardior Pharmaceuticals

Amgen

AstraZeneca

Structure Therapeutics Inc

Eli Lilly

Pfizer

Sanofi

Viking Therapeutics

A couple of big-picture trends in biotech could add up to a nice investment opportunity. First, corporate buyouts are back in style.

Big pharma is looking to fatten profits with buyouts of weight-loss drug companies. Here are 4 candidates.

The future of the U.S. economy appears promising, with robust growth and strong corporate performance. This economic strength has propelled the stock market to record highs, signaling confidence in the economy's resilience.

3 Pharma Stocks That Are Money-Printing Machines in 2024

Ginkgo Bioworks Holdings

Novo Nordisk and Ginkgo Bioworks will work together on manufacturing. Producing more obesity and diabetes medicines is likely a priority.

Novo Nordisk and Ginkgo Bioworks Are Teaming Up. Here's Why That's Bullish for Both Stocks.

A staggering $1 trillion could be the annual cost to the US healthcare system if 40% of Americans with obesity begin treatment with GLP-1 drugs at current prices, according to Dr Jonathan Gruber, the Ford Professor of Economics at the Massachusetts Institute of Technology (MIT). This figure, which rivals the entire budget of the Medicare programme, highlights the potential fiscal challenges posed by these promising yet costly treatments for obesity.

Novo Nordisk and Eli Lilly weight loss drugs may not be a silver bullet, but they have huge potential, says leading US bank

Ozempic usage for weight loss has gone viral, making it the highest revenue-generating drug for Novo Nordisk AV/S NYSE: NVO. Originally purposed for Type 2 diabetes, the skyrocketing off-label use for weight loss led Novo to create Wegovy, a stronger version of Ozempic (generic name: semaglutide) for obesity.

Novo Nordisk Arms Wegovy to Be a Triple Threat

NVIDIA

Ares Management

Cameco

Saia

Nvidia, which bucked the S&P 500 downdraft last week, leads this weekend's watch list of five stocks near buy points.

Nvidia Leads 5 Stocks Near Buy Points As S&P 500 Tests Key Level

BMO Capital Markets initiated coverage on Danish drug maker Novo Nordisk A/S NVO after the company garnered interest as it hit the holy grail with the next generation of famed weight loss and diabetes drugs.

Novo Nordisk's Dominance In Obesity & Diabetes Drug Market Backed by Strong Pipeline: Analyst Gives Outperform Rating - Novo Nordisk (NYSE:NVO)

There is no evidence linking diabetes and weight loss drugs like Ozempic and Wegovy to an increase in suicidal thoughts, the European Union's drug regulator said Friday, the latest findings casting doubt on a link after a probe by U.S. regulators said a “small risk” couldn't be ruled out.

No Evidence Linking Ozempic And Suicidal Thoughts, EU Says

The review examined several drugs from Novo Nordisk, including Wegovy, Ozempic, Rybelsus, and Saxenda, but did not include Eli Lilly's Zepbound and Mounjaro.

EU probe of weight loss and diabetes drugs like Wegovy, Ozempic finds no link to suicidal thoughts

Novo Nordisk and Eli Lilly & Co., the dynamic duo of the weight-loss drug world, still have plenty of upside even after their shares have surged over the past 12 months, BMO Capital Markets analysts said Friday.

Obesity-drug power couple Novo Nordisk and Eli Lilly still have room to run, analysts say

A committee of the European Medicines Agency said Friday that a popular weight-loss drug doesn't increase the risk of suicide.

Popular weight-loss drug doesn't increase suicide risk, EU regulator says

Weight-loss stocks remain the focus of many investors. The GLP-1 drugs that many companies have put forward address key health concerns like obesity and diabetes, which have become epidemics in many Western countries.

Shed the Fat, Gain the Profits: 3 Weight-Loss Stocks to Own Until 2027

Coinbase

General Electric

Johnson & Johnson

Microsoft

If you're wondering which stocks to buy in April, here's a good place to start. The stock market is off to a difficult start in the second quarter.

All-Time High Flyers: 7 Stocks to Buy as the Market Peaks

DexCom

The burgeoning interest in obesity drugs, particularly GLP-1 products such as Ozempic, Saxenda, and Mounjaro, marks a significant shift in the global approach to managing obesity. In this article, we look at three obesity drug stocks investors should consider.

3 Obesity Drug Stocks Set to Skyrocket as Demand Goes Wild

Ascendis Pharma

Cytokinetics

Edwards Lifesciences

Tema Obesity & Cardiometabolic ETF

iShares Nasdaq Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

Medtronic

SPDR S&P 500 ETF Trust

Vertex Pharmaceuticals

Health Care Select Sector SPDR Fund

A new exchange-traded fund needs an edge to attract investors. This might be its industry focus — a tall order in a crowded market with ETFs covering just about any industry you can imagine.

This weight-loss ETF has performed well in its first five months. How does it compare with cheaper alternatives?

Veeva Systems

Novo Nordisk is a leader in fast-growing therapeutic areas. Veeva Systems' services are invaluable to its customers.

2 Healthcare Stocks to Buy Hand Over Fist in April

Health insurers are going to offer coverage for Wegovy to Medicare patients. Beyond weight loss, Wegovy has shown it can reduce the risk of heart attacks and strokes.

Novo Nordisk's Stock Could Get Another Boost, Thanks to This Huge Development

ASML Hld

Diageo

Hermes International

HSBC Holdings

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Nestle SA

Novartis

Prosus NV

Roche Holding AG

SAP SE

Siemens AG

TotalEnergies SE

Unilever

The Mag Seven stocks have powered gains in the U.S. market. Now, the hunt is on for an equivalent group of outperformers elsewhere.

Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.

Catalent

The parent of Wegovy producer Novo Nordisk has refiled an application to the U.S. Federal Trade Commission (FTC) for approval of a $16.5 billion deal to buy manufacturing subcontractor Catalent , a spokesperson said on Monday.

Novo Nordisk parent refiles US application on Catalent deal

Novo Nordisk and Eli Lilly make medicines that target GLP-1, which figures in a number of ailments. A new study found that a similar drug could help treat Parkinson's.

Could This New Development Soon Buoy Eli Lilly and Novo Nordisk Stock?

People with obesity-related heart failure and diabetes can get substantial heart-health benefits from the popular obesity drug Wegovy, even if they don't shed a lot of weight on the medication, according to new research.

Wegovy's heart benefits are not just linked with weight loss, new study suggests

Novo Nordisk dominates the obesity care and diabetes markets thanks to Ozempic, Rybelsus, and Wegovy. Notably, Wegovy was recently granted an expanded indication to treat patients at risk of heart disease.

After Wegovy's Approval to Treat Heart Disease, Novo Nordisk Continues to Make Moves

News for Novo Nordisk Stock (NVO)